17. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PATH study

Authors
Category Primary study
JournalClinical Neurophysiology
Year 2020
This article has no abstract
Epistemonikos ID: 5f9229c6e2e0130b15909c54e3351f7be0f64313
First added on: Feb 11, 2025